Overview

Replacing current manual processing of leukapheresis samples for cell therapy production with a robust, high-precision, automatable, closed system.

GPB Scientific has developed a prototype system that reduces cost and the risk of human error and contamination for the front-end of cell therapy manufacturing... providing lower-variability and higher quality cells for the input to the cell engineering and production processes for CAR-T, and other cell therapies such as NK, Stem Cell.   

The microfluidic chip-based technology licensed exclusively from Princeton University and further developed by GPB into a polymer consumable, uses the principle of Deterministic Lateral Displacement (DLD) to gently and uniformly fractionate and separate cells on the basis of size (more).  The DLD process has been used to fractionate whole blood to harvest components including white blood cells, red blood cells, platelets, rare cells including circulating tumor cells (CTCs), T cells, NK cells, etc.

Our product strategy is to offer a turnkey, closed benchtop system using consumable DLD microfluidic chips to process leukapheresis samples.

Target specifications for the CAR-T therapy DLD system are:

  • Closed Benchtop unit
  • Fully Automated
  • Single-use multi-channel polymer DLD microchips using high-precision/low-cost commercial chip production
  • Up to 5x1010 WBCs in up to 500mL in one hour (10-15L apheresis procedure targeting 1-2x109 mononuclear cells, starting WBC concentration up to 2x108 WBCs/mL)
  • >70% WBC and T-lymphocyte recovery
  • >90% RBC depletion
  • >80% platelet depletion
  • >70% recovery of T-cell expansion capacity
  • Compatible with routine blood collection and storage bags

This simple system will also be able to enrich WBCs for other cell therapies, e.g., stem cell therapies, hematopoetic cell transplantation, NK cells, and others.

How does it work?